The Role of Act1 in the Control of Autoimmunity

The Epigenetics of Autoimmune Diseases

Volumn , Issue , 2009, Pages 55-74

  Jørgensen, Trine N ^a   Giltiay, Natalia V ^a   Johnson, Angela ^a   Li, Xiaoxia ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Act1, controlling autoimmunity; Act1, inhibiting CD40 and BAFFR signalling; Act1, inhibiting systemic autoimmunity; Act1, mediating organ specific autoimmunity; Multiple sclerosis, organ specific autoimmune disease; Single gene polymorphisms and deletions, associating with autoimmunity; Sj gren's syndrome, systemic autoimmune disease; Systemic lupus erythematosus (SLE)

Indexed keywords

EID: 84890166077     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470743553.ch4     Document Type: Chapter

References (72)

1. Rudofsky, U.H. and Lawrence, D.A. (1999) New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environmental Health Perspectives 107 (suppl 5), 713-721.
2. Kotzin, B.L. and Palmer, E. (1987) The contribution of NZW genes to lupus-like disease in (NZB χ NZW)F1 mice. Journal of ExperimentalMedicine 165, 1237-1251.
3. Kono, D.H., Burlingame, R.W., Owens, D.G. et al. (1994) Lupus susceptibility loci in New Zealand mice. Proceedings of the National Academy of Sciences, USA 91, 10168-10172.
4. Rozzo, S.J., Vyse, T.J., Drake, C.G. and Kotzin, B.L. (1996) Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. Proceedings of the National Academy of Sciences, USA 93, 15164-15168.
5. Mohan, C., Alas, E., Morel, L. et al. (1998) Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective, loss of tolerance to H2A/H2B/DNA subnucleosomes. Journal of Clinical Investigation 101, 1362-1372.
6. Andrews, B.S., Eisenberg, R.A., Theofilopoulos, A.N. et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. Journal of ExperimentalMedicine 148, 1198-1215.
7. Murphy, E.D. and Roths, J.B. (1978) Autoimmunity and lymphoproliferation In: Rose, N.R., Bigazzi, P.E., Warner, N.L. (eds), Genetic Control of Autoimmune Disease, pp. 207-220. Elsevier/North Holland Biomedical Press, Amsterdam.
8. Tabbara, K.F. and Vera-Cristo, C.L. (2000) Sjogren syndrome. Current Opinion in Ophthalmology 11, 449-454.
9. Steinman, L. (1996) Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85, 299-302.
10. Gold, R., Linington, C. and Lassmann, H. (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953-1971.
11. Linthicum, D.S. (1982) Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162, 211-220.
12. Batten, M., Groom, J., Cachero, T.G. et al. (2000) BAFF mediates survival of peripheral immature B lymphocytes. Journal of Experimental Medicine 192, 1453-1466.
13. Schiemann, B., Gommerman, J.L., Vora, K. et al. (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111-2114.
14. Mackay, F., Schneider, P., Rennert, P. and Browning, J. (2003) BAFF AND APRIL: a tutorial on B cell survival. Annual Reviews in Immunology 21, 231-264.
15. Banchereau, J., Bazan, F., Blanchard, D. et al. (1994) The CD40 antigen and its ligand. Annual Reviews in Immunology 12, 881-922.
16. Mackay, F., Woodcock, S.A., Lawton, P. et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. Journal of Experimental Medicine 190, 1697-1710.
17. Mehling, A., Loser, K., Varga, G. et al. (2001) Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. Journal of Experimental Medicine 194, 615-628.
18. Pers, J.O., Daridon, C., Devauchelle, V. et al. (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Annals of the New York Academy of Sciences 1050, 34-39.
19. DiDonato, J.A., Hayakawa, M., Rothwarf, D.M. et al. (1997) A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388, 548-554.
20. Mercurio, F., Zhu, H., Murray, B.W. et al. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278, 860-866.
21. Regnier, C.H., Song, H.Y., Gao, X. et al. (1997) Identificationand characterization of an IkappaB kinase. Cell 90, 373-383.
22. Woronicz, J.D., Gao, X., Cao, Z. et al. (1997) IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 278, 866-869.
23. Zandi, E., Rothwarf, D.M., Delhase, M. et al. (1997) TheIkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91, 243-252.
24. Pasparakis, M., Schmidt-Supprian, M. and Rajewsky, K. (2002) IkappaB kinase signaling is essential for maintenance of mature B cells. Journal of Experimental Medicine 196, 743-752.
25. Li, Z.W., Omori, S.A., Labuda, T. et al. (2003) IKK beta is required for peripheral B cell survival and proliferation. Journal of Immunology 170, 4630-4637.
26. Kaisho, T., Takeda, K., Tsujimura, T. et al. (2001) IkappaB kinase alpha is essential for mature B cell development and function. Journal of Experimental Medicine 193, 417-426.
27. Coope, H.J., Atkinson, P.G., Huhse, B. et al. (2002) CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO Journal 21, 5375-5385.
28. Senftleben, U., Cao, Y., Xiao, G. et al. (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293, 1495-1499.
29. Ghosh, S. and Karin, M. (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(suppl.), S81-S96.
30. Claudio, E., Brown, K., Park, S. et al. (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nature Immunology 3, 958-965.
31. Franzoso, G., Carlson, L., Poljak, L. et al. (1998) Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. Journal of Experimental Medicine 187, 147-159.
32. Kayagaki, N., Yan, M., Seshasayee, D. et al. (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17, 515-524.
33. Agarwal, S., Misra, R. and Aggarwal, A. (2008) Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. Journal of Rheumatology 35, 515-519.
34. Iwakura, Y. and Ishigame, H. (2006) The IL-23/IL-17 axis in inflammation. Journal of Clinical Investigation 116, 1218-1222.
35. Lubberts, E., Schwarzenberger, P., Huang, W. et al. (2005) Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. Journal of Immunology 175, 3360-3368.
36. Zhang, Z., Zheng, M., Bindas, J. et al. (2006) Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflammatory Bowel Diseases 12, 382-388.
37. Qian, Y., Qin, J., Cui, G. et al. (2004) Act1, a negative regulator in CD40-and BAFF-mediated B cell survival. Immunity 21, 575-587.
38. Qian, Y., Liu, C., Hartupee, J. et al. (2007) The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nature Immunology 8, 247-256.
39. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G. et al. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317.
40. Sabelko, K.A., Kelly, K.A., Nahm, M.H. et al. (1997) Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. Journal of Immunology 159, 3096-3099.
41. Roths, J.B., Murphy, E.D. and Eicher, E.M. (1984) A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. Journal of Experimental Medicine 159, 1-20.
42. Nishimura, H., Nose, M., Hiai, H. et al. (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151.
43. Salama, A.D., Chitnis, T., Imitola, J. et al. (2003) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 198, 71-78.
44. Fujimoto, M., Tsutsui, H., Xinshou, O. et al. (2004) Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. International Immunology 16, 303-314.
45. Tanaka, K., Ichiyama, K., Hashimoto, M. et al. (2008) Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. Journal of Immunology 180, 3746-3756.
46. Li, X., Commane, M., Nie, H. et al. (2000) Act1, an NF-kappa B-activating protein. Proceedings of the National Academy of Sciences, USA 97, 10489-10493.
47. Leonardi, A., Chariot, A., Claudio, E. et al. (2000) CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proceedings of the National Academy of Sciences, USA 97, 10494-10499.
48. Qian, Y., Zhao, Z., Jiang, Z. and Li, X. (2002) Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cells. Proceedings of the National Academy of Sciences, USA 99, 9386-9391.
49. Novatchkova, M., Leibbrandt, A., Werzowa, J. et al. (2003) The STIR-domain superfamily in signal transduction, development and immunity. Trends in Biochemical Sciences 28, 226-269.
50. Zhao, Z., Qian, Y., Wald, D. et al. (2003) IFN regulatory factor-1 is required for the up-regulation of the CD40-NF-kappa B activator 1 axis during airway inflammation. Journal of Immunology 170, 5674-5680.
51. Qian, Y., Giltiay, N., Xiao, J. et al. (2008) Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. European Journal of Immunology 38, 2219-2228.
52. Mackay, F., Woodcock, S.A., Lawton, P. et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. Journal of Experimental Medicine 190, 1697-1710.
53. Wakeland, E.K., Liu, K., Graham, R.R. and Behrens, T.W. (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15, 397-408.
54. Rozzo, S.J., Allard, J.D., Choubey, D. et al. (2001) Evidence for an interferon-inducible gene, If1202, in the susceptibility to systemic lupus. Immunity 15, 435-443.
55. Stohl, W., Xu, D., Kim, K.S. et al. (2005) BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis & Rheumatism 52, 2080-2091.
56. Fox, P.C. (2007) Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Annals of the New York Academy of Sciences 1098, 15-21.
57. Bossen, C. and Schneider, P. (2006) BAFF, APRIL and their receptors: structure, function and signaling. Seminars in Immunology 18, 263-275.
58. Brink, R. (2006) Regulation of B cell self-tolerance by BAFF. Seminars in Immunology 18, 276-283.
59. Bishop, G.A., Moore, C.R., Xie, P. et al. (2007) TRAF proteins in CD40 signaling. Advances in Experimental Medicine and Biology 597, 131-151.
60. Mackay, F., Woodcock, S.A., Lawton, P. et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. Journal of Experimental Medicine 190, 1697-1710.
61. Mehling, A., Loser, K., Varga, G. et al. (2001) Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. Journal of Experimental Medicine 194, 615-628.
62. Xie, P., Stunz, L.L., Larison, K.D. et al. (2007) Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 27, 253-267.
63. Bishop, G.A. and Xie, P. (2007) Multiple roles of TRAF3 signaling in lymphocyte function. Immunologic Research 39, 22-32.
64. Xu, L.G. and Shu, H.B. (2002) TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. Journal of Immunology 169, 6883-6889.
65. Hauer, J., Puschner, S., Ramakrishnan, P. et al. (2005) TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proceedings of the National Academy of Sciences, USA 102, 2874-2879.
66. Chang, S.H., Park, H. and Dong, C. (2006) Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. Journal of Biological Chemistry 281, 35603-35607.
67. Hartupee, J., Liu, C., Novotny, M. et al. (2007) IL-17 enhances chemokine gene expression through mRNA stabilization. Journal of Immunology 179, 4135-4141.
68. Hofstetter, H.H., Ibrahim, S.M., Koczan, D. et al. (2005) Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cellular Immunology 237, 123-130.
69. Park, H., Li, Z., Yang, X.O. et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology 6, 1133-1141.
70. Dong, Y. and Benveniste, E.N. (2001) Immune function of astrocytes. Glia 36, 180-190.
71. Yao, Z., Spriggs, M.K., Derry, J.M. et al. (1997) Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9, 794-800.
72. Schwandner, R., Yamaguchi, K. and Cao, Z. (2000) Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. Journal of Experimental Medicine 191, 1233-1240.